Patents by Inventor Zhijian LV

Zhijian LV has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20240308992
    Abstract: Provided are a compound as represented by formula I serving as a DRK2 inhibitor, or a stereoisomer or optical isomer, a pharmaceutically acceptable salt, a prodrug or a solvate thereof. Further provided are a preparation method for the compound, a pharmaceutical composition thereof, and the use thereof as a Drak2 inhibitor and in the preparation of a drug for preventing and/or treating a Drak2-related disease.
    Type: Application
    Filed: May 13, 2024
    Publication date: September 19, 2024
    Inventors: Zhijian LV, Li ZHONG
  • Publication number: 20240275492
    Abstract: Provided is an underwater wireless optical communication system. The system includes an emitting end and a receiving end; where the emitting end includes a beam emitting module and an optical phased array, where the beam emitting module is configured to emit a communication beam obtained by modulating communication information, and the optical phased array is configured to adjust an emission direction of the communication beam; and the receiving end includes a tracking module and an information demodulation module, where the tracking module is configured to receive a target communication beam emitted after adjustment by the optical phased array and align the target communication beam, and the information demodulation module is configured to demodulate the received target communication beam to obtain the communication information.
    Type: Application
    Filed: October 25, 2022
    Publication date: August 15, 2024
    Inventors: ZHIJIAN LV, LULU ZHA, JINPENG TIAN, WENWEI ZHANG
  • Patent number: 12057889
    Abstract: Provided is an underwater wireless optical communication system. The system includes an emitting end and a receiving end; where the emitting end includes a beam emitting module and an optical phased array, where the beam emitting module is configured to emit a communication beam obtained by modulating communication information, and the optical phased array is configured to adjust an emission direction of the communication beam; and the receiving end includes a tracking module and an information demodulation module, where the tracking module is configured to receive a target communication beam emitted after adjustment by the optical phased array and align the target communication beam, and the information demodulation module is configured to demodulate the received target communication beam to obtain the communication information.
    Type: Grant
    Filed: October 25, 2022
    Date of Patent: August 6, 2024
    Assignee: SHENZHEN TECHNOLOGY UNIVERSITY
    Inventors: Zhijian Lv, Lulu Zha, Jinpeng Tian, Wenwei Zhang
  • Patent number: 12015443
    Abstract: Provided is a visible light communication system. The system includes a modulation and light emission module configured to emit a communication light ray obtained by modulating information to be communicated; and a tracking and light sensing module configured to receive and demodulate the communication light ray to obtain the information to be communicated and further configured to align the tracking and light sensing module with the communication light ray according to the angle between the tracking and light sensing module and the communication light ray.
    Type: Grant
    Filed: October 25, 2022
    Date of Patent: June 18, 2024
    Assignee: SHENZHEN TECHNOLOGY UNIVERSITY
    Inventors: Zhijian Lv, Lulu Zha, Jinpeng Tian, Wenwei Zhang
  • Publication number: 20240088999
    Abstract: Provided is a visible light communication system. The system includes a modulation and light emission module configured to emit a communication light ray obtained by modulating information to be communicated; and a tracking and light sensing module configured to receive and demodulate the communication light ray to obtain the information to be communicated and further configured to align the tracking and light sensing module with the communication light ray according to the angle between the tracking and light sensing module and the communication light ray.
    Type: Application
    Filed: October 25, 2022
    Publication date: March 14, 2024
    Inventors: ZHIJIAN LV, LULU ZHA, JINPENG TIAN, WENWEI ZHANG
  • Publication number: 20230203059
    Abstract: The present invention relates to a macrocyclic JAK inhibitor and the uses thereof. Specifically, the present invention relates to a compound represented by formula I, or a stereoisomer or an optical isomer, a pharmaceutically acceptable salt, or a prodmg or a solvate thereof; and also relates to a pharmaceutical composition of the compound, and the medical uses thereof as a JAK inhibitor and in the preparation of a drug for preventing and/or treating diseases related to JAK, especially JAK3.
    Type: Application
    Filed: May 21, 2021
    Publication date: June 29, 2023
    Inventors: Zhijian LV, Jia LI, Mingbo SU, Anhui GAO
  • Patent number: 11667704
    Abstract: The invention relates to the field of medical biotechnology. Specifically, the present invention relates to a fusion protein containing an anti-interleukin-17 antibody and a tumor necrosis factor receptor extracellular region, a polynucleotide encoding the fusion protein, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, and the use of the fusion protein for the treatment, prevention, and/or diagnosis of a related disease in an individual.
    Type: Grant
    Filed: November 6, 2018
    Date of Patent: June 6, 2023
    Assignees: BEIJING BEYOND BIOTECHNOLOGY CO., LTD, HANGZHOU POLYMED BIOPHARMACEUTICALS, INC.
    Inventors: Pinliang Hu, Jing Zou, Weidong Hong, Yun He, Jie Bai, Lingyun Song, Wendi Yang, Zhijian Lv, Shaoyun Xiang
  • Publication number: 20230167114
    Abstract: The present invention relates to a macrocyclic JAK inhibitor and the use thereof. The present invention specifically relates to a compound as shown in formula I, or a stereoisomer or optical isomer thereof, a pharmaceutically acceptable salt thereof, and a prodrug or solvate thereof, and also relates to a pharmaceutical composition of the compound and the medical use thereof as a JAK inhibitor, and in the preparation of medicaments for preventing and/or treating diseases related to JAK, especially JAK1.
    Type: Application
    Filed: May 21, 2021
    Publication date: June 1, 2023
    Inventors: Zhijian LV, Jia LI, Mingbo SU, Anhui GAO
  • Publication number: 20210261654
    Abstract: The invention relates to the field of medical biotechnology. Specifically, the present invention relates to a fusion protein containing an anti-interleukin-17 antibody and a tumor necrosis factor receptor extracellular region, a polynucleotide encoding the fusion protein, a vector comprising the polynucleotide, a host cell comprising the polynucleotide or the vector, and the use of the fusion protein for the treatment, prevention, and/or diagnosis of a related disease in an individual.
    Type: Application
    Filed: November 6, 2018
    Publication date: August 26, 2021
    Inventors: Pinliang HU, Jing ZOU, Weidong HONG, Yun HE, Jie BAI, Lingyun SONG, Wendi YANG, Zhijian LV, Shaoyun XIANG